These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 17174384

  • 1. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
    Wahl H, Tan L, Griffith K, Choi M, Liu JR.
    Gynecol Oncol; 2007 Apr; 105(1):104-12. PubMed ID: 17174384
    [Abstract] [Full Text] [Related]

  • 2. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [Abstract] [Full Text] [Related]

  • 3. Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria.
    Gao X, Deeb D, Jiang H, Liu YB, Dulchavsky SA, Gautam SC.
    J Exp Ther Oncol; 2005 Jun; 5(1):39-48. PubMed ID: 16416600
    [Abstract] [Full Text] [Related]

  • 4. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M.
    Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
    [Abstract] [Full Text] [Related]

  • 5. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.
    Cancer Res; 2006 Jun 01; 66(11):5867-74. PubMed ID: 16740726
    [Abstract] [Full Text] [Related]

  • 6. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
    Frese S, Schüller A, Frese-Schaper M, Gugger M, Schmid RA.
    Anticancer Res; 2009 Aug 01; 29(8):2905-11. PubMed ID: 19661294
    [Abstract] [Full Text] [Related]

  • 7. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis.
    Deeb DD, Jiang H, Gao X, Divine G, Dulchavsky SA, Gautam SC.
    J Exp Ther Oncol; 2005 Aug 01; 5(2):81-91. PubMed ID: 16471035
    [Abstract] [Full Text] [Related]

  • 8. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
    Petrucci E, Pasquini L, Petronelli A, Saulle E, Mariani G, Riccioni R, Biffoni M, Ferretti G, Benedetti-Panici P, Cognetti F, Scambia G, Humphreys R, Peschle C, Testa U.
    Gynecol Oncol; 2007 May 01; 105(2):481-92. PubMed ID: 17292950
    [Abstract] [Full Text] [Related]

  • 9. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
    Panichakul T, Intachote P, Wongkajorsilp A, Sripa B, Sirisinha S.
    Anticancer Res; 2006 May 01; 26(1A):259-65. PubMed ID: 16475706
    [Abstract] [Full Text] [Related]

  • 10. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A.
    Cancer Res; 2006 May 15; 66(10):5363-70. PubMed ID: 16707463
    [Abstract] [Full Text] [Related]

  • 11. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH.
    Biochem Pharmacol; 2009 Apr 15; 77(8):1328-36. PubMed ID: 19426671
    [Abstract] [Full Text] [Related]

  • 12. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.
    Cancer Res; 2004 Jul 15; 64(14):4900-5. PubMed ID: 15256461
    [Abstract] [Full Text] [Related]

  • 13. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
    Iacomino G, Medici MC, Russo GL.
    Anticancer Res; 2008 Jul 15; 28(2A):855-64. PubMed ID: 18507029
    [Abstract] [Full Text] [Related]

  • 14. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
    Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S, Mukhtar H.
    Oncogene; 2008 Mar 27; 27(14):2055-63. PubMed ID: 17998943
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells.
    Woods DC, Alvarez C, Johnson AL.
    Gynecol Oncol; 2008 Mar 27; 108(3):632-40. PubMed ID: 18191995
    [Abstract] [Full Text] [Related]

  • 16. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
    Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A.
    Br J Cancer; 2003 Jul 07; 89(1):206-14. PubMed ID: 12838325
    [Abstract] [Full Text] [Related]

  • 17. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.
    Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC, Schmid RA.
    Oncogene; 2003 Aug 21; 22(35):5427-35. PubMed ID: 12934102
    [Abstract] [Full Text] [Related]

  • 18. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS, Kemp TJ.
    Cancer Chemother Pharmacol; 2003 Sep 21; 52(3):175-84. PubMed ID: 12811515
    [Abstract] [Full Text] [Related]

  • 19. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells.
    Lippa MS, Strockbine LD, Le TT, Branstetter DG, Strathdee CA, Holland PM.
    Apoptosis; 2007 Aug 21; 12(8):1465-78. PubMed ID: 17440816
    [Abstract] [Full Text] [Related]

  • 20. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J.
    Biochem Pharmacol; 2009 Mar 01; 77(5):804-12. PubMed ID: 19100720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.